Dr. Lynda Szczech, VP of Clinical Development and Medical Affairs at FibroGen discusses new data presented at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined on roxadustat, the company’s investigational first-in-class oral treatment for anemia in patients with chronic kidney disease (CKD). These data will build upon roxadustat’s well-defined efficacy and safety profile. If approved in December 2020, roxadustat will be the first new anemia treatment option for CKD patients in about 30 years. Its oral formulation could make anemia management more convenient for patients and limit time spent in transfusion facilities, an especially important consideration during flu season and the COVID-19 pandemic.
Lynda Szczech is Vice President of Clinical Development and Medical Affairs at FibroGen. As a nephrologist with over 25 years of clinical and research experience, she has more than 160 peer-reviewed publications, having studied many of the issues involved with anemia and cardiovascular disease, as well as complications of chronic kidney disease (CKD) and issues with public policy and decision making related to end stage kidney disease (ESKD). In addition to serving on the ASN’s Public Policy Board as well as Communications Committee, Dr. Szczech was the Chair of the Dialysis Advisory Group for the ASN as well as the President of the National Kidney Foundation.